insulin glulisine

(redirected from Apidra)
Also found in: Medical.

insulin glu·li·sine

 (glo͞o′lĭ-sēn′)
n.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by the substitution of lysine for asparagine and glutamic acid for lysine in the B chain, used in the treatment of type 1 and type 2 diabetes.

[glu(tamic acid) + alteration of lysine.]
References in periodicals archive ?
The Global Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) was valued US$ 27.4 billion in 2018, and is projected to exhibit a CAGR of 7.2% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.
The total insulin dose at discharge was 11 units/day (7 units of Novolin R short-acting insulin and 4 units of Apidra ultra-rapid-acting insulin).
The product, which delivers 1 to 30 units per injection, can be used with Lantus (insulin glargine), Apidra (insulin glulisine) or Insuman (recombinant human insulin).
Onset, h Peak, h Duration, h Rapid-acting analogs Insulin lispro (Humalog) <0.25-0.5 0.5-2.5 3-5 Insulin aspart (Novolog) <0.25 1-3 3-5 Insulin glulisine (Apidra) <0.25 0.75-2 3-5 Short-acting Regular insulin, CZI, 0.5-1 2-3 5-8 soluble Intermediate-acting NPH, isophane 2-4 4-10 10-16 Long-acting analogs Insulin glargine (Lantus) 2 Relatively 11-24 flat Insulin detemir (Levemir) 1-2 Relatively Dose dependent flat 12 h for 0.2 U/kg 14 h for 0.4 U/kg range 7.6-24 h
This product is in adjacent space to Sanofi's top selling Lantus and Apidra insulin products that also are available in the form of SoloSTAR injection pens.
This product is in an adjacent space to Sanofi's top selling Lantus and Apidra insulin products that also are available in the form of SoloSTAR injection pens.
Rapid and short-acting insulin: Insulin lispro (Humalog), asparte (Novorapid), and glulisine (Apidra) are all analogue insulin--they have an altered molecular structure that allows rapid absorption following subcutaneous injection.
Diversified healthcare company Sanofi (Euronext:SAN) on Friday reported data from a 60-week, open-label study, the 'All to Target' study, that evaluated two Lantus and Apidra regimens as compared with premixed regimen for treatment of uncontrolled type 2 diabetes.
Sanofi reported a 7.6% increase in second-quarter profit on higher sales of its Lantus and Apidra diabetes treatments.
Launched initially in Australia, and now worldwide, the product dispenses the famous Lantus long-lasting insulin, as well as the shorter-acting Apidra brand.